NovoCure Ltd (NVCR) — SEC Financial Statements & Analysis

NovoCure Ltd (NVCR) is a surgical & medical instruments & apparatus company. NovoCure Ltd trades on Nasdaq as: NVCR. NovoCure Ltd (NVCR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-23. Based on that filing, NovoCure Ltd carries a market cap of $1.76B, a P/E ratio of -11.83x, a P/B ratio of 5.20x, a P/S ratio of 2.51x, an enterprise value of $1.65B, and an EV/EBITDA multiple of -11.98x. On profitability, it posts a gross margin of 76.13%, an operating margin of -22.08%, a net margin of -21.25%, a Return on Equity (ROE) of -43.22%, a Return on Assets (ROA) of -14.56%, and a Return on Invested Capital (ROIC) of -29.51%. Per share, it reports EPS of $-1.28, diluted EPS of $-1.28, free cash flow per share of $-0.22, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 10.95% year-over-year, net income growth of -13.09% year-over-year, and EPS growth of -16.42% year-over-year. On the balance sheet, it maintains a current ratio of 2.89x, a quick ratio of 2.70x, working capital of $417.81M, a debt-to-equity ratio of 1.35x, a debt ratio of 0.57, an interest coverage ratio of -15.01x, free cash flow of $-25.43M (TTM), and net debt of $-103.62M. Figures sourced from SEC EDGAR.

Market Cap

$1.76B

P/E TTM

-11.83x

EPS TTM

$-1.28

P/B TTM

5.20x

ROE TTM

-43.22%

ROA TTM

-14.56%

Debt To Equity

1.35x

Free Cash Flow TTM

$-25.43M

Net Revenue TTM Growth 1Y

10.95%

Data as of 2026-06-30 · Source: SEC EDGAR